VenatoRx Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- VenatoRx Pharmaceuticals's estimated annual revenue is currently $15.5M per year.
- VenatoRx Pharmaceuticals received $42.0M in venture funding in July 2017.
- VenatoRx Pharmaceuticals's estimated revenue per employee is $201,000
- VenatoRx Pharmaceuticals's total funding is $107M.
Employee Data
- VenatoRx Pharmaceuticals has 77 Employees.
- VenatoRx Pharmaceuticals grew their employee count by -4% last year.
VenatoRx Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $40.6M | 202 | -2% | N/A | N/A |
#2 | $74.6M | 371 | 19% | N/A | N/A |
#3 | $11.7M | 58 | 14% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.4M | 221 | -2% | N/A | N/A |
#6 | $12.5M | 62 | 7% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $18.3M | 91 | 6% | N/A | N/A |
#9 | $59.9M | 298 | 23% | N/A | N/A |
#10 | $12.9M | 64 | 10% | N/A | N/A |
What Is VenatoRx Pharmaceuticals?
Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$107M
Total Funding
77
Number of Employees
$15.5M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
VenatoRx Pharmaceuticals News
Venatorx Pharmaceuticals, Inc., a Malvern, PA-based private, clinical-stage pharmaceutical company focused on improving health outcomes for...
"Adaptive Phage Therapeutics and Venatorx Pharmaceuticals are poised to change the treatment landscape for drug-resistant infections," said AMR...
Venatorx is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant...
MALVERN, Pa.--(BUSINESS WIRE)--. VenatoRx Pharmaceuticals today announced that Joseph C. Larsen, Ph.D. has joined the Company as ...
Other Companies in Malvern
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.8M | 77 | 24% | N/A |
#2 | $23M | 80 | 5% | N/A |
#3 | $11.6M | 80 | -9% | N/A |
#4 | $22.1M | 82 | -11% | N/A |
#5 | $16.5M | 82 | 41% | N/A |
VenatoRx Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-07-26 | $42.0M | B | Versant Ventures | Article |
VenatoRx Pharmaceuticals Executives
| Name | Title |
|---|---|
| Tim Henkel | Chief Medical Officer |
| Tony Meehan | Chief Business Officer |
| Christopher Burns | President and Chief Executive Officer |
| Ezra Felker | Chief Operating Officer |
| James Murphy | Chief Financial Officer |
| Daniel Pevear | Founder and Senior Vice President, Biology and Grants Development |
| Mary Dorr | VP of Clinical Science |
| Heather Hunter | Vice President, Communications |
| Christopher Burns | President and Chief Executive Officer |
| Susan Emeigh | Vice President, Non-Clinical Safety |
| Larry Rosen | Vice President Pharmaceutical Product Development |
| Stephen Condon | Vice President, Chemistry |
| Jennifer Nelson | Vice President, R&D Program Management |
| Brian Bentley | Vice President Regulatory Affairs |
| Paul McGovern | Senior Vice President Medical Sciences |
| Scott McConnell | Vice President Medical Affairs |
| Jennifer Ellis | sVP Quality |
| Greg Moeck | Vice President, Microbiology |
| Will Sargent | SVP, Commercial Strategy |
| Chitrananda Abeygunawardana | VP, Regulatory Affairs |